4/15
12:39 pm
fate
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag [Yahoo! Finance]
Medium
Report
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag [Yahoo! Finance]
4/14
08:35 am
fate
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) [Yahoo! Finance]
High
Report
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) [Yahoo! Finance]
4/14
08:00 am
fate
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
High
Report
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
4/2
04:01 pm
fate
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
3/11
02:07 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/9
05:09 am
fate
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target [Yahoo! Finance]
Medium
Report
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target [Yahoo! Finance]
3/6
11:16 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at Stifel Nicolaus from $5.00 to $3.00. They now have a "hold" rating on the stock.
Medium
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at Stifel Nicolaus from $5.00 to $3.00. They now have a "hold" rating on the stock.
3/6
09:20 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at Wells Fargo & Company from $5.00 to $4.00. They now have an "equal weight" rating on the stock.
High
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at Wells Fargo & Company from $5.00 to $4.00. They now have an "equal weight" rating on the stock.
3/6
09:20 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
High
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
3/6
08:12 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
High
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
3/5
07:06 pm
fate
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates [Yahoo! Finance]
High
Report
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates [Yahoo! Finance]
3/5
04:01 pm
fate
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
High
Report
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
3/4
04:01 pm
fate
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
3/3
11:02 pm
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
2/14
04:01 pm
fate
Fate Therapeutics to Present at Upcoming Investor Conferences
Medium
Report
Fate Therapeutics to Present at Upcoming Investor Conferences
2/5
04:04 am
fate
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
2/4
04:01 pm
fate
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)